China is a commercial market with enormous potential for the biopharmaceutical industry but is transitioning from a national regulatory environment to one that is harmonized with the global industry, albeit with some local specifics and complexities. BioPhorum’s Post-Approval Strategy Team has been navigating this new Chinese regulatory environment through its many recent changes. To capture its learnings, the team has produced a poster titled...
Viewing related articles
Jun 2022 |
BioPhorum’s Post-Approval Strategy Team has produced a poster titled What is changing in China CMC Regulatory? It refers to a wide range of changes in areas such as pharmacopeia, e.g., more convergent monographs in CHP 2020 than any other version of the Chinese Pharmacopeia. It also talks about changes in submissions, including excipients and primary packaging materials need to be registered on the Chinese Drug Master File platform before use in products. It can be used by BioPhorum member organizations, displayed in a CMC regulatory office, used at CMC meetings, and shared with colleagues outside the regulatory function.
As regulatory complexity and scrutiny continue to grow, collaborative industry bodies are, without doubt, the most effective way for industry to determine how to meet regulatory guidance through ‘strength in numbers’ using a ‘common voice’. This is at the core of BioPhorum’s approach.
Since 2017, it has been mandatory for suppliers of APIs, excipients and packaging materials to register their material in China on the DMF registration platform. While many agencies ask for details of a component’s quality and its impact on products, the Chinese requirements for ‘high risk’ materials, such as those used in biopharmaceuticals, also ask for historical information that is typically proprietary which many suppliers are reluctant to share. This paper summarizes the requirements for raw materials in other ICH countries and compares these to the Chinese approach. The paper also lists all of the details needed for the Chinese registration of biopharmaceutical products’ raw materials in a single place, to help suppliers register their products into this vast market.